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Cytopiloynewas identified as a novel polyacetylenic compound.However, its antidiabetic properties are poorly understood.The aim
of the present study was to investigate the anti-diabetic effect and mode of action of cytopiloyne on type 2 diabetes (T2D). We first
evaluated the therapeutic effect of cytopiloyne on T2D in db/db mice. We found that one dose of cytopiloyne reduced postprandial
glucose levels while increasing blood insulin levels. Accordingly, long-term treatment with cytopiloyne reduced postprandial
blood glucose levels, increased blood insulin, improved glucose tolerance, suppressed the level of glycosylated hemoglobin A1c
(HbA1c), and protected pancreatic islets in db/db mice. Next, we studied the anti-diabetic mechanism of action of cytopiloyne.
We showed that cytopiloyne failed to decrease blood glucose in streptozocin- (STZ-)treated mice whose 𝛽 cells were already
destroyed. Additionally, cytopiloyne dose dependently increased insulin secretion and expression in 𝛽 cells. The increase of insulin
secretion/expression of cytopiloyne was regulated by protein kinase C𝛼 (PKC𝛼) and its activators, calcium, and diacylglycerol
(DAG).Overall, our data suggest that cytopiloyne treats T2Dvia regulation of insulin production involving the calcium/DAG/PKC𝛼
cascade in 𝛽 cells. These data thus identify the molecular mechanism of action of cytopiloyne and prove its therapeutic potential in
T2D.
1. Introduction
Insulin is indispensable for glucose homeostasis inmammals.
Insulin biosynthesis at transcriptional and translational lev-
els, and its secretion in 𝛽 cells, is well regulated by blood
glucose [1]. Calcium ions, potassium ions, phospholipase
C, DAG, phosphatidylinositol triphosphate (IP3), PKC, and
protein kinase A (PKA) are involved in insulin secretion
and, likely, insulin biosynthesis in pancreatic 𝛽 cells [2]. On
binding to insulin, an insulin receptor initiates a signaling
cascade and eventually causes glucose uptake in peripheral
tissues. Any defect in insulin synthesis/secretion or action,
or both, may result in hyperglycemia, a major pathological
feature of type 2 diabetes (T2D) [3]. Such hyperglycemia
is detrimental to 𝛽 cells and insulin target tissues, and this
glucotoxicity is clinically relevant as a cause of diabetes-
related complications such as nephropathy, retinal blindness,
neuropathy, peripheral gangrene, and cardiovascular disease
[4]. Therefore, maintenance of glycemic homeostasis is the
most common therapeutic aim for patients with T2D.
Diabetes is a life-threatening metabolic disease, afflicting
around 5% of the world population. Over 90% of the diabetic
population is diagnosed with T2D mellitus [5, 6]. Current
antihyperglycemic drugs are insulin secretagogues, insulin
sensitizers, inhibitors of sugar cleavage, and glucagon-like
peptide-1 (GLP-1), all of which control homeostasis of blood
sugar by different mechanisms [7]. Common drawbacks
of such drugs include significant side effects, decreased
efficacy over time, low cost-effectiveness, and only partial
anti-diabetic effect of each individual drug [8]. Of note,
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secretagogues with the ability to prevent adverse effects
(e.g., weight gain and hypoglycemia), to stimulate insulin
biosynthesis, or to protect 𝛽 cells from death are rare [7,
9]. GLP-1, an injectable peptide drug, may be the only one
reported to fit these criteria [10]. In view of patients’ welfare,
there is still an obvious need for development of antidiabetics
that protect against hypoglycemia, enhance insulin synthesis,
or improve 𝛽-cell protection.
Plants are an extraordinary resource for anti-diabetic
remedies [11, 12]. One outstanding example is metformin, a
derivative of guanidine that was first isolated from French
lilac and is a commonly prescribed insulin sensitizer for
treatment of T2D [13]. Further, extracts prepared from the
plant Bidens pilosa, a member of the Asteraceae family, were
shown to have anti-diabetic properties in alloxan-treated
mice [14] and have been used to treat patients with diabetes in
America,Africa, andAsia [11, 15]. Twopolyacetylenes isolated
from B. pilosa have demonstrated anti-diabetic properties
by two different laboratories [16, 17]. More recently, another
polyacetylene, cytopiloyne, was identified in B. pilosa and
shown to be highly potent in the prevention of type 1 diabetes
via T-cell regulation [18].B. pilosa and its three polyacetylenes
showed glucose-lowering activities in diabetic mice [16, 19,
20]. However, the long-term therapy andmechanism of these
three polyacetylenes for T2D are not known.
The db/db mice whose leptin receptor gene is mutated
spontaneously develop diabetes because of insulin resistance
[21]. STZ-treated mice represent a chemical-inducible model
that exhibits insufficient insulin production [22]. Both mod-
els reflect main causes of T2D [23]. In this study, we studied
the anti-diabetic potential and mechanism of cytopiloyne in
db/db mice and STZ-treated C57BLmice and in pancreatic 𝛽
cells.
2. Materials and Methods
2.1. Ethics Statement. All animals were maintained and
handled according to the institutional guidelines and the
protocol was approved by the Academia Sinica Ani-
mal Care and Utilization Committee (protocol number:
OMiIBAYW2010043).
2.2. Chemicals, Cells, and Animals. Dimethyl sulfoxide
(DMSO), STZ, nimodipine, EGTA, metformin, glimepiride,
brefeldin A, hematoxylin, eosin, phorbol 12-myristate 13-
acetate (PMA), glimepiride, 1-stearoyl-2-arachidonoyl-sn-
glycerol, cholesterol, and diaminobenzidine tetrahydrochlo-
ride were purchased from Sigma-Aldrich (MO, USA). Anti-
actin, anti-HA, and anti-insulin antibodies were purchased
from Santa Cruz Biotechnology (CA, USA). Insulin (Novo
Nordisk, NJ, USA) and anti-PKC𝛼 (Abcam, MA, USA) and
antiphospho-PKC𝛼 (Millipore, MA, USA) antibodies were
purchased. Cytopiloyne was prepared to 98% purity from B.
pilosa as previously described [17, 18]. Cytopiloyne dissolved
in DMSO was stored in a light protected vial at −20∘C. After
one year storage, more than 90% of the isolated cytopiloyne
was stable, as was confirmed by structural determination
by NMR spectroscopy. RIN-m5F cells (CRL-11605), a rat 𝛽-
cell line, were obtained from the American Type Culture
Collection. Primary pancreatic islets were isolated from
fasted Wistar rats obtained from the National Laboratory
Animal Center (NLAC) in Taipei, Taiwan. C57BL and db/db
mice [24] were obtained from the NLAC. All animals were
maintained in the institutional animal facility and handled
according to the guidelines of the Academia Sinica Institu-
tional Animal Care and Utilization Committee.
2.3. Drug Administration in db/db Mice. For single-dose
administration, diabetic db/db males aged 6 to 8 weeks, with
free access to food, were grouped and tube fed with either
0.2mL vehicle (1𝜇L DMSO per 1mL of PBS), cytopiloyne
(0.1, 0.5, and 2.5mg/kg body weight (BW)), or glimepiride
(2.5mg/kg BW). After 0.5 h, the levels of postprandial blood
sugar and insulin from the mice were monitored for an
additional 4 h. For continuous administration, diabetic db/db
males were grouped and tube-fed with vehicle, cytopiloyne
(0.5 or 2.5mg/kg/day), or glimepiride (2.5mg/kg/day) for
the indicated time, while levels of blood sugar, insulin, and
glycosylated HbA1c and glucose tolerance in these mice were
determined. Unless otherwise indicated, themice were fasted
for 16 h and then postprandial blood glucose and insulin in
these mice were measured. A portion of mice were sacrificed
for immunohistochemical staining.The rest weremaintained
to determine survival rates.
2.4. Drug Administration in STZ-Treated Mice. To deplete
pancreatic 𝛽 cells in mice, 6-week-old C57BL females
were intraperitoneally injected with STZ at 200mg/kg.
STZ-treated females with postprandial blood sugar over
500mg/dL were grouped. Each group was either tube-fed
with vehicle (1𝜇L DMSO per 1mL of PBS), cytopiloyne (0.1,
0.5, and 2.5mg/kg), or glimepiride (2.5mg/kg) or injected
with insulin at 2.5 IU/kg BW. Blood glucose levels were
monitored for 4 h. To distinguish sensitizer activity from
releaser activity of cytopiloyne, STZ-treatedC57BLmicewere
tube-fed with vehicle, glimepiride (2.5mg/kg), metformin
(60mg/kg), and cytopiloyne (0.5 and 2.5mg/kg) 1 h before
insulin injection (2.5 IU/kg). Blood glucose levels in the mice
were monitored from 0 to 4 h after insulin injection.
2.5. Measurement of Glucose, Insulin, and HbA1c. Glucose
levels in mouse blood samples were measured using an Elite
glucometer (Bayer, PA, USA). Insulin levels in blood samples
or islet cell supernatants were determined by ELISA assays
(Mercodia, Uppsala, Sweden). The levels of glycosylated
HbA1c in blood samples were measured using a DCA 2000
analyzer (Bayer, PA, USA).
2.6. Insulin Secretion. Pancreatic islets (10 islets/mL) from
fasted male Wistar rats were incubated with Krebs-Ringer
bicarbonate (KRB) buffer [25] containing vehicle (1𝜇L
DMSO per mL KRB buffer), glimepiride, or cytopiloyne in
the absence or presence of glucose for 30min.TheKRB buffer
was then collected for ELISA assays.
2.7. Intraperitoneal Glucose Tolerance Test (IPGTT). Male
db/db mice were administered either vehicle, cytopiloyne at
0.5 and 2.5mg/kg/day, or glimepiride at 2.5mg/kg/day for
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the indicated time. The mice were fasted for 16 h before the
glucose tolerance test. On days 0 and 42, each group received
an oral dose (0.2mL) of vehicle (1𝜇LDMSOper 1mL of PBS),
glimepiride, or cytopiloyne (time 0) and one intraperitoneal
injection with glucose (0.5 g/kg) 0.5 h later. The levels of
blood sugar were monitored from −0.5 to 3 h after glucose
administration.
2.8. Immunohistochemistry. Pancreata from db/db males
with continuous drug administration were snap frozen in
OCT compound and stained with hematoxylin and eosin
or anti-insulin antibody, followed by diaminobenzidine
tetrahydrochloride development as previously published [18].
Optimal cutting temperature compound (OCT) is an inert
cryosection medium. Multiple parallel sections of each pan-
creas were analyzed by light microscopy.
2.9. Intracellular Staining for Insulin. Rat pancreatic islets
were incubated with vehicle alone (1𝜇L DMSO per 1mL of
PBS), cytopiloyne, or glimepiride for 24 h.The islet cells were
dissociated into single-cell suspension, stained with anti-
insulin antibody and analyzed by fluorescence-activated cell
sorting (FACS).
2.10. Real-Time RT-PCR Analysis. Rat pancreatic islets were
incubated with vehicle (1𝜇L DMSO per 1mL of PBS),
cytopiloyne, or glimepiride for 24 h. Total RNA isolated from
these islets was extracted and converted to cDNA. Real-
time RT-PCR was performed with the above cDNA using
insulin primers (5󸀠-TGCGGGTCCTCCACTTCAC-3󸀠 and
5󸀠-GCCCTGCTCGTCCTCTGG-3󸀠) or L13 primers (5󸀠-AGA
TAC CAC ACC AAG GTC CG-3󸀠 and 5󸀠-GGA GCA GAA
GGC TTC CTG-3󸀠).
2.11. Transfection and Luciferase Assays. The phINS-Luc
and pRL-TK plasmids contain the human insulin promoter
(2347 bp) from the phINS-DCR3 vector [26] linked to the
firefly luciferase gene and the thymidine kinase promoter
linked to the Renilla luciferase reporter gene, respectively.
RIN-m5F cells were transfected with pHACE-PKC𝛼 DN
plasmid (a gift from Dr J.-W. Soh), pcDNA3 (a control
plasmid), phINS-Luc, and/or pRL-TK by lipofectamine or
electroporation. After a 24 h recovery, the cells were treated
with vehicle (1𝜇L DMSO per 1mL of medium), glucose,
GF109203X (a PKC inhibitor), glimepiride, or cytopiloyne for
an additional 24 h. Subsequently, dual luciferase assays were
performed as described [18].
2.12. Detection of Intracellular Calcium. RIN-m5F cells were
preloaded with Fura 2-AM (5 𝜇M) in modified Krebs-
Henseleit buffer for 30min at 25∘C for 1 h. After washing,
the cells were stimulatedwith 16.7mMglucose or cytopiloyne
(7, 14, and 28𝜇M). Intracellular calcium was measured using
a fluorescence spectrophotometer (CAF 110, Jasco, Tokyo,
Japan) at the excitation wavelengths of 340 and 380 nm and
emission wavelength of 500 nm. The ratio of fluorescence
intensity at 340 nm to that at 380 nm represents the level of
intracellular calcium.
2.13. Extraction and Measurement of DAG. RIN-m5F cells
were treatedwith glucose, cytopiloyne, PMA, and glimepiride
for 5min. Total lipids were extracted with ethyl acetate as
previously described [27].The cells were separated on a silica
thin layer plate with the first developer of ethyl acetate : acetic
acid : trimethylpentane (9 : 2 : 5) and the second developer
of hexane : diethylether :methanol : acetic acid (90 : 20 : 3 : 2).
The spot of DAG and cholesterol in each sample was visu-
alized with 15% sulfuric acid and identified by 1-stearoyl-2-
arachidonoyl-sn-glycerol and cholesterol.
2.14.Western Blot. RIN-m5F cells were starved in KRB buffer
for 30min. The cells were then treated with vehicle, PMA,
16.7mM glucose, and cytopiloyne in the absence or presence
of EGTA and nimodipine for the indicated time. After exten-
sive washing, the cells were pelleted.The total lysate, cytosolic
fraction, and membrane fraction were prepared, followed by
SDS-polyacrylamide gel electrophoresis. The membrane was
blotted with anti-PKC𝛼, anti-phospho-PKC𝛼, and anti-actin
antibodies. The expression level of HA-tagged PKC𝛼-DN in
RIN-m5F cells was confirmed using Western blot with anti-
HA antibody.The effect of GF109203X on PKC𝛼 inactivation
in 𝛽 cells was confirmed by Western blot (see the species list
in the Supplementary Material of Figure 1 available online at
http://dx.doi.org/10.1155/2013/685642).
2.15. Statistical Analysis. Data from three independent exper-
iments or more are presented as mean± SEM. ANOVA was
used for statistical analysis of differences between groups,
and 𝑃 (∗) less than 0.05 was considered to be statistically
significant.
3. Results
3.1. Beneficial Effect of Cytopiloyne on Glucose Lowering, Glu-
cose Tolerance Test, Glycosylation of HbA1c, and Islet Preser-
vation. We and others have previously identified three poly-
acetylenes present in B. pilosa that exhibit antihyperglycemic
activities in different diabetic models [16–20]. However, their
long-term benefit and mode of action remained unclear. In
the study, we investigated the therapeutic effect and mecha-
nism of cytopiloyne, a polyacetylenic glucoside (Figure 1(A)),
on T2D. Glimepiride, an anti-diabetic sulfonylurea drug, acts
to enhance insulin secretion in pancreatic 𝛽 cells and, in
turn, reduces blood glucose. We first evaluated single-dose
effects of cytopiloyne on diabetic db/db mice. We found
that like glimepiride (2.5mg/kg), cytopiloyne at doses of 0.1,
0.5, and 2.5mg/kg significantly reduced postprandial blood
glucose levels in a dose-dependent manner in diabetic db/db
mice (Table 1). We also compared blood insulin levels in the
same mice. Both glimepiride and cytopiloyne significantly
elevated the blood insulin levels in db/db mice compared
to vehicle alone (Table 2). These data showed that a single
dose of cytopiloyne had anti-hyperglycemic and insulin-
releasing effects on db/db mice. Next, we investigated long-
term therapeutic effects of cytopiloyne in diabetic db/db
mice.We found that 0.5mg/kg cytopiloyne had similar blood
sugar-lowering effects on fed db/db mice as glimepiride
at 2.5mg/kg (Figure 1(B)). Additionally, cytopiloyne was
4 Evidence-Based Complementary and Alternative Medicine
∗
∗
∗ ∗ ∗
∗
∗ ∗
∗
∗
∗
0 1 2 3 4 6
Time (weeks)
0
10
20
30
40
Bl
oo
d 
in
su
lin
 (𝜇
g/
L)
Vehicle (𝑛 = 6)
GLM 2.5mg/kg (𝑛 = 6)
CP 0.5mg/kg (𝑛 = 6)
CP 2.5 mg/kg (𝑛 = 6)
−30 0 30 60 90 120 150 180
200
400
600
800
BG
 (m
g/
dL
)
Drug Glu
Time (min)
Vehicle (𝑛 = 6)
GLM 2.5mg/kg (𝑛 = 6)
CP 0.5mg/kg (𝑛 = 6)
CP 2.5 mg/kg (𝑛 = 6)
Week 0
−30 0 30 60 90 120 150 180
200
400
600
800
BG
 (m
g/
dL
)
Drug
Glu
Time (min)
Vehicle (𝑛 = 6)
GLM 2.5mg/kg (𝑛 = 6)
CP 0.5mg/kg (𝑛 = 6)
CP 2.5 mg/kg (𝑛 = 6)
Week 6
∗
Week 0 Week 6
0
2
4
6
8
10
H
bA
1
c
(%
)
∗
∗
GLM 2.5mg/kg (𝑛 = 6)
CP 0.5mg/kg (𝑛 = 6)
CP 2.5mg/kg (𝑛 = 6)
HO HO
HO
HO
O
O
OH
(A)
(C)
(D)
(E)
Cytopiloyne
0 1 2 3 4 6
20
40
60
80
Time (weeks)
BG
 (m
g/
dL
)
Vehicle
GLM 2.5mg/kg (𝑛 = 6)
CP 0.5mg/kg (𝑛 = 6)
mg/kg (𝑛 = 6)CP 2.5
∗
(B)
Vehicle (𝑛 = 6)
(𝑛 = 6)
Figure 1: Continued.
Evidence-Based Complementary and Alternative Medicine 5
(a)
(b)
(i) (k) (m) (o)
(p)(n)(l)(j)
(d) (f) (h)
(c) (e) (g)
PBS GLM 2.5mg/kg CP 0.5mg/kg CP 2.5mg/kg
(F)
H
 &
 E
H
 &
 E
H
 &
 I
H
 &
 I
Figure 1: Anti-diabetic effects of cytopiloyne in db/db mice during long-term treatment. (A) Chemical structure of cytopiloyne. (B) Four
groups of 6 to 8-week-old diabetic db/db mice were tube-fed with vehicle, cytopiloyne (CP, 0.5 and 2.5mg/kg/day), or glimepiride (GLM,
2.5mg/kg/day) from 0 to 6 weeks. Postprandial blood glucose (BG) levels in these mice were measured. (C) Blood insulin levels from the
above mice (B). (D) IPGTT was performed in the above db/db mice (B) on weeks 0 and 6 after-treatment, and blood glucose levels were
monitored for 3.5 h. (E) The percentage of glycosylated HbA1c in whole blood from the above mice (B) was determined 0 and 6 weeks after-
treatment. (F) Pancreata of 8- and 16-week-old db/db males, which had received the same treatment as described in (B) for 2 (images a–h)
and 10 (images i–p) weeks, were stained with hematoxylin and eosin (H&E, images (a), (c), (e), (g), (i), (k), (m), and (o)) or hematoxylin and
an antibody against insulin (H&I, images (b), (d), (f), (h), (j), (l), (n), and (p)). Arrowheads indicate pancreatic islets. Scale bars, 200 𝜇m.
Results are expressed as mean ± SEM from 3 independent experiments, and 𝑃 (∗) < 0.05 was considered to be statistically significant. The
number of mice (n) is indicated in parentheses.
slightly more efficacious at 2.5mg/kg than glimepiride at
2.5mg/kg. Consistently, cytopiloyne increased blood insulin
levels to a greater extent than glimepiride and this increase
was dose dependent (Figure 1(C)). We also evaluated the
effect of cytopiloyne on glucose tolerance. IPGTT assays
showed no difference in glucose tolerance in treated and
control mice at week 0 (upper panel, Figure 1(D)). By con-
trast, cytopiloyne treatment for 6 weeks improved glucose
tolerance in db/db mice to a greater extent than glimepiride
at the same dose (2.5mg/kg) (lower panel, Figure 1(D)).
Glycosylated HbA1c is known to be an excellent indicator
of long-term glycemic control. Therefore, we examined the
percentage of glycosylated HbA1c in db/db mice following
different treatments. In the blood from 6- to 8-week-old
db/db mice, 4.8% HbA1c was glycosylated. However, by 12
to 14 weeks of age, this value had risen to 7.3% in untreated
db/db mice. By contrast, 6.3%, 6%, and 5.6% of HbA1c were
glycosylated in the blood of age-matched mice following
treatment with 2.5mg/kg glimepiride or with 0.5mg/kg
or 2.5mg/kg cytopiloyne, respectively (Figure 1(E)). These
data suggest that cytopiloyne, which reduced glycosylated
HbA1c by 1.3% and 1.7% at concentrations of 0.5mg/kg or
2.5mg/kg, respectively, achieves relatively tighter glycemic
control than glimepiride, which only decreased glycosylated
HbA1c by 1%, in db/db mice. Diabetic db/db mice usually
develop severe atrophy of pancreatic islets. We assessed the
protective effect of cytopiloyne on islet destruction in db/db
mice aged 8 and 16 weeks, which corresponded to early
and chronic stages of diabetes, respectively [28]. There was
no significant difference in pancreatic islets of treated and
untreated db/db mice at 6 to 8 weeks of age. Twelve- to
14-week-old db/db mice, which had received a long-term
treatment with vehicle control and glimepiride, had sporadic
islets. In sharp contrast, the age-matched db/db mice with
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Table 1: Blood glucose levels following a single oral dose of
cytopiloyne in fed db/db mice. Diabetic db/db mice aged 6 to 8
weeks, with free access to food, were grouped and tube-fed with
vehicle, glimepiride (GLM) at 2.5mg/kg/day, and cytopiloyne (CP)
at 0.1, 0.5, and 2.5mg/kg/day. A half-hour after tube feeding was
set as time 0. Blood samples were collected from the mice at the
indicated time intervals (0, 1, 2, and 4 h). The blood glucose levels
were determined using a glucometer.The number of mice (𝑛) tested
is indicated in parentheses in the first column.
Treatment Blood glucose level (mg/dL)
0 1 2 4 (h)
Vehicle (𝑛 = 8) 365 ± 9 309 ± 4 281 ± 9 240 ± 11
GLM 2.5mg/kg (𝑛 = 5) 378 ± 9 237 ± 16∗ 178 ± 20∗ 187 ± 6∗
CP 0.1mg/kg (𝑛 = 7) 373 ± 6 267 ± 12 204 ± 17∗ 158 ± 18∗
CP 0.5mg/kg (𝑛 = 7) 369 ± 27 214 ± 15∗ 163 ± 8∗ 132 ± 11∗
CP 2.5mg/kg (𝑛 = 7) 365 ± 9 207 ± 11∗ 147 ± 12∗ 129 ± 11∗
∗
𝑃 < 0.05 as determined by ANOVA.
cytopiloyne treatment showed much greater preservation of
islet structure (Figure 1(F)). Accordingly, cytopiloyne treat-
ment resulted in a better survival rate as compared to
treatment with glimepiride or vehicle in db/db mice (see
the species list in the Supplementary Material of Table 1
available online at http://dx.doi.org/10.1155/2013/685642).We
also confirmed the preventive effect of cytopiloyne on T2D in
db/db mice aged 4 weeks that has been previously reported
[29, 30]. Cytopiloyne failed to stop the development of
T2D in db/db mice, but it significantly reduced hyper-
glycemia in these mice compared to the control cohort (see
the species list in the Supplementary Material of Figure 2
available online at http://dx.doi.org/10.1155/2013/685642). It
should be noted that the blood glucose levels of db/db
mice in preventive experiments (see the species list in
the Supplementary Material of Figure 2(a) available online
at http://dx.doi.org/10.1155/2013/685642) and therapeutic
experiments (Figure 1(B)) were dissimilar because the ages of
the mice examined were different. Collectively, cytopiloyne
treatment for diabetes was better than glimepiride in terms
of both dosage and therapeutic effects.
3.2. Cytopiloyne Acts as an Insulin Secretagogue rather than a
Sensitizer. The sugar-reducing and insulin-increasing effects
of cytopiloyne raised the possibility that cytopiloyne controls
blood sugar in db/db mice primarily through stimulating
insulin production from 𝛽 cells. Rat primary pancreatic
islets are commonly used to test insulin secretion/synthesis
because rats have more abundant pancreatic islets than mice
and the islets of both species respond to glucose similarly
[1]. To examine the role of cytopiloyne in insulin secretion,
we treated rat islets with cytopiloyne in KRB buffer con-
taining 16.7mM glucose. We found that cytopiloyne effec-
tively enhanced insulin secretion in high glucose medium
(Figure 2(a)) as well as glucose-free and low-glucose media
(see the species list in the SupplementaryMaterial of Figure 3
available online at http://dx.doi.org/10.1155/2013/685642). To
confirm that cytopiloyne reduced hyperglycemia by stimu-
lating insulin production from pancreatic 𝛽 cells in vivo, we
tested its ability to reduce hyperglycemia and to augment
insulin levels in STZ-treated C57BL mice whose 𝛽 cells were
already depleted. As expected, cytopiloyne lost its ability
to regulate both responses in these mice (Figure 2(b)). In
sharp contrast, insulin treatment still diminished blood glu-
cose levels in 𝛽-cell-depleted mice (Figure 2(b)). To exclude
the possibility that cytopiloyne is an insulin sensitizer, we
administrated STZ-treated C57BL/6 mice with an oral dose
of vehicle, glimepiride, metformin, or cytopiloyne 60min
before an insulin injection. Both cytopiloyne and glimepiride
had little, if any, lowering effect on blood sugar in these mice.
However, metformin, an anti-diabetic biguanide drug, acts to
sensitize insulin signaling and, in turn, significantly reduced
blood glucose levels compared to vehicle alone in these
mice (Figure 2(c)). Overall, our results support an insulin-
releasing role of cytopiloyne in 𝛽 cells.
3.3. Cytopiloyne Elevates the Level of Insulin mRNA and
Protein in Pancreatic Islets. Glucose is known to modu-
late transcription, translation, and secretion of insulin in
pancreatic 𝛽 cells [1]. However, current secretagogues act
to increase insulin secretion but not synthesis. We have
shown that cytopiloyne increases insulin secretion from rat
islets (Figure 2(a)). Therefore, we also evaluated the effect of
cytopiloyne on insulin expression. We first used an insulin
promoter-driven reporter construct to test the effect of
different treatments on insulin transcription. Glimepiride
had no significant effect on insulin transcription in RIN-
m5F 𝛽 cells, a rat 𝛽-cell line, compared to the low-glucose
control (3.3mM). By contrast, high glucose (16.7mM) upreg-
ulated insulin transcription eleven times; 28𝜇M cytopiloyne
augmented insulin transcription five times, and this increase
was dose dependent (Figure 3(a)). Next, we examined the
expression levels of insulin mRNA relative to those of L13, a
house-keeping control gene, in rat islet cells pretreated with
low glucose, high glucose, 10 𝜇M glimepiride, or cytopiloyne
at 7, 14, and 28𝜇M for 24 h. Glimepiride slightly decreased
insulin transcription. By contrast, a high concentration of
glucose up-regulated insulin transcription five times, while
28𝜇M cytopiloyne resulted in doubled insulin transcription
(Figure 3(b)). Further, we examined the effect of cytopiloyne
on insulin content inside pancreatic islet cells. FACS is a
sensitive method to detect levels of an intracellular protein
at the level of an individual cell. Therefore, we used FACS
to monitor the content of intracellular insulin. Glucose
treatment (16.7mM) increased the intracellular insulin levels
in these cells from 2.3% to 5.1% (Figure 3(c)). Consistent
with the effect of cytopiloyne on insulin transcription, 28𝜇M
cytopiloyne increased the intracellular insulin levels 5-fold
compared to control treatment in these cells, and this effect on
insulin content was dose dependent (Figure 3(c)).The overall
data suggest that cytopiloyne stimulates insulin expression in
pancreatic 𝛽 cells.
3.4. Cytopiloyne Increases Calcium Influx, DAG Generation,
and PKC𝛼 Activation. Secondary messengers such as cal-
cium andDAG are involved in a variety of signaling pathways
in 𝛽 cells [31–35]. We wanted to understand the mechanism
of cytopiloyne in the insulin expression and the release in
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Table 2: Blood insulin levels following a single oral dose of cytopiloyne in fed db/db mice. Diabetic db/db mice aged 6 to 8 weeks received
the same treatment as those in Table 1. Blood samples at the indicated time interval (0, 0.5, 1, 2, and 4 h) were collected from the mice and the
insulin levels in each blood sample were determined using ELISA kits.The number of mice (𝑛) is indicated in parentheses in the first column.
Treatment Blood insulin level (𝜇g/L)
0 0.5 1 2 4 (h)
Vehicle (𝑛 = 8) 13.8 ± 1.9 11.5 ± 1.9 10.3 ± 2.4 8.3 ± 0.7 8.6 ± 1.9
GLM 2.5mg/kg (𝑛 = 6) 13.9 ± 1.2 19.3 ± 4.2 26.3 ± 3.3∗ 15.9 ± 1.7∗ 11.8 ± 2.1∗
CP 0.1mg/kg (𝑛 = 5) 17.2 ± 4.7 21.0 ± 1.3∗ 15.5 ± 0.6∗ 14.1 ± 0.5 9.7 ± 1.3
CP 0.5mg/kg (𝑛 = 5) 15.7 ± 1.9 22.6 ± 1.9∗ 16.0 ± 2.4∗ 12.8 ± 0.7∗ 12.2 ± 1.9
CP 2.5mg/kg (𝑛 = 5) 12.5 ± 1.2 25.5 ± 1.2∗ 18.9 ± 3.3∗ 17.6 ± 1.7∗ 8.9 ± 2.1
∗
𝑃 < 0.05 as determined by ANOVA.
𝛽 cells. Our data showed that RIN-m5F cells responded
to glucose and cytopiloyne in a similar way to primary
rat islet cells (Figures 3(a) and 3(b)). Therefore, we used
RIN-m5F cells to test the effect of cytopiloyne on calcium
mobilization. We found that 16.7mM glucose significantly
increased intracellular calcium in 𝛽 cells (Figure 4(a)). Simi-
larly, cytopiloyne increased the level of intracellular calcium
in a dose-dependent manner (Figure 4(a)). Next, we deter-
mined the effect of cytopiloyne on the production of lipids,
DAG, and cholesterol, in RIN-m5F cells. PMA, glimepiride,
and 16.7mM glucose significantly increased the level of DAG
in comparisonwith the vehicle control (Figure 4(b)). Of note,
cytopiloyne dose dependently increased the level of DAG
but not cholesterol (Figure 4(b)). Because PKC𝛼 has been
previously implicated in insulin secretion of 𝛽 cells [31, 33],
we next assessed the effect of cytopiloyne on PKC𝛼 activation
by examining its translocation and phosphorylation. Like
PMA and 16.7mM glucose, cytopiloyne dose dependently
increased the membrane portion of PKC𝛼 (Figure 4(c)).
Besides, like PMA, cytopiloyne increased the phosphoryla-
tion of PKC𝛼 (Figure 4(d)). This increase was abolished by
nimodipine, a calcium channel blocker, and EGTA, a calcium
chelator (Figure 4(d)). The data suggest that cytopiloyne
activates PKC𝛼 through an increase of its activators, calcium
and DAG.
3.5. Cytopiloyne Increases Insulin Secretion and Transcrip-
tion via PKC𝛼. Next, we tested whether PKC𝛼 regulated
cytopiloyne-mediated insulin secretion in 𝛽 cells. We found
that cytopiloyne stimulated insulin secretion in 𝛽 cells, simi-
lar towhatwas observed in positive controls, 16.7mMglucose
and PMA (Figure 5(a)). By contrast, GF109203X, a PKC
inhibitor, inhibited cytopiloyne- and PMA-induced insulin
secretion (Figure 5(a)). Accordingly, overexpression of a
dominant-negative mutant of PKC𝛼 decreased cytopiloyne-
and PMA-mediated insulin secretion (Figure 5(b)). On the
contrary, overexpression of this mutant only slightly, if at all,
inhibited glucose-mediated insulin secretion (Figure 5(b)).
These data showed that cytopiloyne increased insulin secre-
tion in 𝛽 cells in a PKC𝛼-dependent manner. We also tested
the involvement of PKC𝛼 in insulin transcription in 𝛽 cells.
We found that like 16.7mM glucose and PMA, cytopiloyne
stimulated insulin transcription in 𝛽 cells (Figure 5(c)).
GF109203X completely abolished cytopiloyne-, glucose-, and
PMA-mediated insulin transcription (Figure 5(c)). Similarly,
overexpression of a dominant-negative PKC𝛼 significantly
inhibited insulin transcription (Figure 5(d)). These data
revealed that cytopiloyne increased insulin transcription in
𝛽 cells via PKC𝛼. Furthermore, we tested whether calcium
mobilization affected cytopiloyne-mediated insulin secre-
tion.We found that calcium intervention inhibited the insulin
secretion by cytopiloyne in RIN-m5F cells (Figure 5(e))
and rat 𝛽 pancreatic islets (see the species list in the
Supplementary Material of Figure 4 available online at
http://dx.doi.org/10.1155/2013/685642).
In summary, our mechanistic data suggest that cytopi-
loyne enhances insulin secretion and expression in 𝛽 cells via
the regulation of PKC𝛼 by calcium and DAG.The increase of
insulin production in 𝛽 cells and islet protection is associated
with the therapy of cytopiloyne for T2D (Figure 6).
4. Discussion and Conclusions
Plants provide a promising source of anti-diabetic medicines.
Cytopiloyne, a plant polyacetylene, represents a new class
of anti-diabetic chemotherapeutics. This study not only
demonstrates the anti-diabetic efficacy of cytopiloyne, but
also reveals the mechanism of the anti-diabetic actions of
cytopiloyne in cell and mouse models.
Cytopiloyne has several unique benefits over current
secretagogues in the market, including enhancement of
insulin expression and maintenance of islet architecture.
First, nutrients such as glucose can stimulate insulin biosyn-
thesis at transcriptional and translational levels and the
secretion of insulin in 𝛽 cells [1, 36]. However, current
secretagogues for diabetes can stimulate insulin secretion
but not insulin biosynthesis. Unexpectedly, cytopiloyne can
increase the level of insulin mRNA and protein, and it
may be functionally superior to sulfonylureas (Figure 3).
Second, cytopiloyne improved islet protection and resulted
in a higher survival rate of db/db mice than glimepiride
or vehicle control (Figure 1(F) and see the species list
in the Supplementary Material of Table 1 available online
at http://dx.doi.org/10.1155/2013/685642). Similarly, cytopi-
loynewas reported tomaintain pancreatic islet architecture in
NODmice, a type 1 diabetesmodel [18].Whether cytopiloyne
employs the samemechanism in prevention of 𝛽 cell death in
both types of diabetes needs to be further investigated.
Cytopiloyne has other advantages over glimepiride. First,
cytopiloyne is a relatively potent anti-diabetic compound
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Figure 2: Cytopiloyne-mediated insulin secretion depends on pancreatic 𝛽 cells. (a) Rat pancreatic islets were incubated with KRB buffer
containing vehicle, glimepiride (GLM, 0 to 10𝜇M), or cytopiloyne (CP, 1.5 to 42 𝜇M) in the absence or presence of 16.7mM glucose (HG).The
insulin levels were determined using an insulin ELISAkit.Thedata are presented asmean± SEMof 3 independent experiments. (b) FedC57BL
mice, which had already received an injection of STZ, were administered an oral dose of vehicle, cytopiloyne (CP, 0.1, 0.5, and 2.5mg/kg),
and an intraperitoneal injection of insulin (Ins, 2.5 IU/kg). Postprandial blood sugar levels in the STZ-treated mice were determined using
a glucometer. (c) Fed C57BL mice, which had already received STZ, were orally administered a single dose of vehicle, cytopiloyne (CP, 0.5
and 2.5mg/kg), glimepiride (GLM, 2.5mg/kg), or metformin (Met, 60mg/kg), followed by an intraperitoneal injection with insulin (Ins).
Postprandial blood sugar levels in the STZ-treated mice were determined using a glucometer. Results are expressed as mean± SEM from 3
independent experiments, and 𝑃 < 0.05 was considered to be statistically significant (∗). The number of mice (𝑛) is indicated in parentheses.
as compared to glimepiride. Cytopiloyne induced similar
anti-diabetic effects as glimepiride at one-fifth of the dose
and modestly better anti-diabetic effects at the same dose
(Figure 1 and Tables 1 and 2). In comparison with low-
potency insulin secretagogues, cytopiloyne may have other
benefits such as increased efficacy or decreased toxicity. Sec-
ond, cytopiloyne may have a different mechanism of action
as that of glimepiride, based on the large differences in their
chemical structures. In fact, cytopiloyne, but not glimepiride,
is able to promote insulin transcription (Figure 3) and con-
fer islet protection (Figure 1(F)). Cytopiloyne is structurally
different from currently known secretagogues and thus may
represent a new class of anti-diabetic agents. Thus, studying
the anti-diabetic mechanism of cytopiloyne may elucidate
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Figure 3: Increase in insulin mRNA and protein content by cytopiloyne in pancreatic islets. (a) RIN-m5F 𝛽 cells transfected with phINS-Luc
and pRL-TK plasmids were incubated with medium containing 3.3mM glucose in the presence of vehicle (LG), glimepiride (GLM, 10𝜇M),
and cytopiloyne (7, 14, or 28 𝜇M) or 16.7mM glucose (HG). Insulin promoter activity expressed as fold change relative to vehicle-treated
control was measured using dual luciferase assays. (b)The relative expression level (R.E.L.) of insulin relative to L13 in rat primary pancreatic
islets, which were already treated with 3.3mM glucose in the presence of vehicle (LG), glimepiride (GLM, 10𝜇M), or cytopiloyne (7, 14, or
28 𝜇M) or 16.7mM glucose (HG) for 24 h, was determined by real-time RT-PCR. (c) Rat pancreatic islets received the same treatments as the
islets in (b) in the presence of brefeldin A for 24 h. After anti-insulin antibody staining, these cells underwent FACS analysis. The percentage
of insulin-positive 𝛽 cells is shown. Results are expressed as mean± SEM from 3 independent experiments, and 𝑃 < 0.05 was considered to
be statistically significant (∗).
novel pathways that participate in insulin synthesis/secretion
and islet preservation and the development of anti-diabetic
agents.
No drug is perfect, and cytopiloyne presents chal-
lenges like other therapies. Current secretagogues occa-
sionally reduce blood sugar to a detrimental degree, a
condition known as hypoglycemia. The development of
blood glucose-dependent secretagogues would prevent this
dangerous side effect. At a low dose (e.g., 3 𝜇M), cytopi-
loyne stimulates insulin secretion in pancreatic islets in
a glucose-dependent manner (see the species list in the
Supplementary Material of Figure 3 available online at
http://dx.doi.org/10.1155/2013/685642). However, a high dose
of cytopiloyne can still stimulate insulin secretion to some
extent even in the absence of glucose (Figure 2(a)). The data
show that cytopiloyne-mediated insulin secretion is partially
glucose dependent. Thus, at a high dose, cytopiloyne may
pose a similar potential risk for hypoglycemia as sulfony-
lureas, particularly in patients with low blood glucose levels.
However, this problemmay be alleviated by decreased dosage
or use in combination with a sensitizer such as metformin,
which has no hypoglycemic effect. Additionally, it should be
10 Evidence-Based Complementary and Alternative Medicine
HG 7 14 28
CP (𝜇M)
0
0.02
0.04
0.06
0.08
0.10
3
4
0
/3
80
nm
(a)
CHL DAG Cell lipid
CHL
DAG
0
1
2
3
4
D
AG
 (f
ol
ds
)
∗
∗
∗
∗
∗
∗
∗
∗
Glu − − − − − − − HG
CP (𝜇M) 0 00 03 7 14 28
PMA (𝜇M) 0
0 00
0 0
0
0
0
0
0
0 0
0
1
GLM (𝜇M) 10
(b)
NS PMA HG
PKC 𝛼
Actin
Ratio 1.0 1.3 1.6 1.5 4.8 1.3
CP 7 CP 14 CP 28
(c)
0
0
0
0 0 0 0
0 0 0
0
0
0
0 0 0
0 0
28 28 28
1 1
11 1
10 10
1.0 5.1 2.1 1.6 0.7 1.4 1.4
CP (𝜇M)
PMA (𝜇M)
EGTA(𝜇M)
pPKC 𝛼
tPKC 𝛼
Ratio
Nimo. (𝜇M)
(d)
Figure 4: Effects of cytopiloyne on calcium mobilization, DAG generation, and PKC𝛼 activation. (a) After Fura 2-AM loading, RIN-m5F
cells were stimulated with 16.7mM glucose (HG) and cytopiloyne (CP) at 7, 14, and 28𝜇M. The level of intracellular calcium, as shown by
the 340/380 nm ratio, was detected using a fluorescence spectrophotometer. (b) RIN-m5F cells were stimulated with glucose, cytopiloyne
(CP), PMA, and glimepiride (GLM). Total cell lipids and their commercial standards, DAG and cholesterol (CHL), were resolved on a silica
thin layer plate. The quantity of DAG and cholesterol in each sample is replotted into histograms. (c) RIN-m5F cells were incubated with
vehicle (NS), cytopiloyne (CP, 7, 14, and 28 𝜇M), PMA (1 𝜇M), and 16.7mM glucose (HG). Membrane proteins of each sample were subjected
to Western blot with anti-PKC𝛼 and anti-actin antibodies. (d) RIN-m5F cells were incubated with vehicle, cytopiloyne (28 𝜇M), and PMA
(1 𝜇M) in the absence or presence of EGTA (10𝜇M) and nimodipine (Nimo, 1 𝜇M). Total proteins were subjected to Western blot with anti-
PKC𝛼 (t-PKC𝛼) and anti-phospho-PKC𝛼 (p-PKC𝛼) antibodies.
noted that insulin secretagogues have a low clinical incidence
of hypoglycemia, because patients with T2D usually have
higher insulin resistance than healthy subjects.
Cytopiloyne contains a glucose moiety and therefore it
is conceivable that it acts at glucose receptors to mediate
insulin expression and secretion. However, our data argue
against this possibility. At 28𝜇M, the concentration of glucose
in cytopiloyne is about 600 times lower than the glucose in
our experiments (16.7mM).However, upregulation of insulin
transcription by cytopiloyne at the same concentration is
40% (not 0.17%) of the up-regulation by 16.7mM glucose
(Figures 3(a) and 3(b)). Notably, 28𝜇M cytopiloyne was less
effective in inducing insulin mRNA production but more
effective in increasing insulin protein levels than 16.7mM
glucose in islets (Figure 3). This discrepancy may be due
to differences in the regulation of insulin at the mRNA
and protein levels by cytopiloyne. Indeed, glucose and GLP-
1 strongly stimulate insulin translation but only modestly
stimulate insulin transcription in 𝛽 cells [1, 37].
DAG and calcium are common secondary messengers in
𝛽 cells [31–35]. Both messengers activate PKC𝛼. PKC𝛼 has
been found to be involved in insulin secretion mediated by
PMA and glucose [31–35] although the authors of one study
excluded the participation of PKC𝛼 in glucose-mediated
insulin secretion [31–35]. Consistent with the literature, our
study shows that PMA activates PKC𝛼 in 𝛽 cells to a greater
extent than glucose (Figure 4(c)). In this study, cytopiloyne
dose dependently activated PKC𝛼 (Figures 4(c) and 4(d)).
PKC𝛼 activation of cytopiloyne was dependent on calcium
(Figure 4(d)) and probably also DAG. Furthermore, interfer-
ence with the PKC inhibitor, GF109203X, and the dominant-
negative mutant of PKC𝛼 inhibited cytopiloyne-mediated
insulin secretion/expression in 𝛽 cells (Figures 5(a)–5(d)).
The insulin secretion/expression of cytopiloyne is calcium
dependent (Figure 5(e)). Therefore, our data suggest that
cytopiloyne increases insulin production via PKC𝛼 activation
that involves secondary messengers (Figure 6).
In conclusion, we showed that cytopiloyne suppressed
the progression of T2D in db/db mice as evidenced by
the decrease in the levels of blood glucose and HbA1c,
glucose tolerance, and islet atrophy in db/db mice. Insulin
release/expression and protection of 𝛽 cells contributed
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Figure 5: Cytopiloyne-mediated insulin secretion and expression are abolished by a dominant-negative mutant and a PKC𝛼 inhibitor. (a)
RIN-m5F cells were grown in medium with 16.7mM glucose (HG) or 3.3mM glucose (LG) in the presence of PMA (1𝜇M), GF109203X
(GF, 3𝜇M), and cytopiloyne (CP, 28 𝜇M). The insulin level in the supernatants was determined using an ELISA kit. (b) RIN-m5F cells were
transfected with 5 𝜇g of pHACE-PKC𝛼DN (+) or pcDNA3 (−) plasmid and grown in medium supplemented with 16.7mM (HG) or 3.3mM
glucose (LG) in the presence of PMA and cytopiloyne.The insulin level was determined as described in (a).The expression level of dominant-
negativeHA-tagged PKC𝛼 (DN) and an internal control, actin, in the transfected cells was determined byWestern blot using anti-HAand anti-
actin antibodies. (c) RIN-m5F cells were transfected with phINS-Luc and pRL-TK plasmids. The cells were grown in medium with 16.7mM
(HG) or 3.3mM glucose (LG) in the absence and presence of PMA, GF109203X, and cytopiloyne.The activity of the insulin promoter (pINS)
in foldwasmeasured using dual luciferase assays. (d) RIN-m5F cells were transfectedwith phINS-Luc and pRL-TKplus 5𝜇g of pHACE-PKC𝛼
DN (+) or pcDNA3 (−) plasmids. The cells were grown in medium with 16.7mM (HG) or 3.3mM glucose (LG) in the absence or presence
of PMA and cytopiloyne. Insulin promoter activity expressed as fold change relative to vehicle-treated control was measured using dual
luciferase assays. The expression level of dominant-negative HA-tagged PKC𝛼 (DN) and actin in the transfected cells was determined using
Western blot and anti-HA and anti-actin antibodies. (e) RIN-m5F cells were grown inmediumwith 3.3mM glucose (LG) and/or cytopiloyne
(CP, 28 𝜇M) in the presence of EGTA (10𝜇M) or nimodipine (Nimo, 1 𝜇M). The insulin level in the supernatants was determined.
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Figure 6: Schematic diagram of the likely mechanism by which
cytopiloyne treats T2D in diabetic mouse models. Cytopiloyne
shows anti-diabetic effects in diabetic mice, as evidenced by a
reduction in the levels of blood sugar and glycosylated HbA1c,
improvement of glucose tolerance, and its regulation of 𝛽-cell
functions (e.g., insulin secretion, insulin expression, and pancreatic
islet protection). The regulation of insulin secretion/expression in 𝛽
cells by cytopiloyne involves PKC𝛼 and its activators, calcium, and
DAG.
to this suppression. We also showed that cytopiloyne up-
regulated insulin release/expression that involved PKC𝛼 acti-
vation and its activators, calcium and likely DAG. This study
reveals the anti-diabetic mode of action of cytopiloyne and
suggests its use as a new anti-diabetic agent.
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